In This Article:
-
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) and GeneTx Biotherapeutics LLC announced interim data from the Phase 1/2 study in pediatric patients with a genetically confirmed diagnosis of full maternal UBE3A gene deletion.
-
Interim results demonstrate a meaningful improvement in clinical disease and an acceptable safety profile.
-
7/9 patients showed improvement on the disease scale from Baseline in at least 3 of 5 domains and the overall score.
-
Six patients exhibited a decrease in severity in at least 2 of 5 domains and the overall score.
-
Also See: Ultragenyx Sells One-Third Of Future North American Crysvita Royalties For $500M.
-
There have been no treatment-related serious adverse events of any type nor adverse events related to lower extremity weakness observed in these patients.
-
Cerebrospinal fluid (CSF) protein levels have remained stable.
-
These interim data support a protocol amendment to the Phase 1/2 study approved in the U.K. and Canada to initiate additional new cohorts of patients at higher monthly loading doses.
-
The study has begun enrollment and has dosed the first patient in these new cohorts.
-
Ultragenyx also announced it has exercised its option to acquire GeneTx and has closed on the acquisition for an upfront payment of $75.0 million plus future milestone and royalty payments.
-
Price Action: RARE shares closed 5.76% lower at $61.02 on Monday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.